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Abstract
Here we described a paclitaxel (PTX) nanocrystals formulation using D-α-tocopheryl
polyethylene glycol 1000 succinate (TPGS) as the sole excipient for overcoming multidrug
resistance (MDR), a key challenge in current cancer therapy. To the best of our knowledge, it is
the first report on PTX nanocrystals which can reverse MDR. TPGS serves as a surfactant to
stabilize the nanocrystals and a P-gp inhibitor to reverse MDR. The size and morphology of the
nanocrystals were studied by transmission electron microscopy and the crystalline structure was
determined by powder X-ray diffraction. In vitro drug release profile showed that the nanocrystals
exhibited sustained release kinetics compared to Taxol which is the clinical paclitaxel formulation.
The cytotoxicity and antitumor efficacy in xenograft models were also investigated. It is
demonstrated that PTX/TPGS nanocrystals have significant advantages over Taxol in achieving
better therapeutic effect in Taxol-resistant cancer cells both in vitro and in vivo, which was also
confirmed by apoptosis assays. We envision that further development of this type of nanocrystals
will provide a novel strategy for drug delivery and multidrug resistance treatment.
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Introduction
Paclitaxel (PTX) is a potent antineoplastic agent against a wide variety of malignancies [1].
It has been approved by US FDA for the treatment of breast cancer, ovarian cancer and non-
small-cell lung cancer (NSCLC) [2]. However, multidrug resistance (MDR) developed by
cancer cells still represents a major challenge in the clinical cure of cancer by PTX alone or
in combination with other antineoplastic agents, especially advanced and metastatic forms.
Elevated expression and activity of the ATP-binding cassette (ABC) transporter has been
identified as an important reason for the failure of PTX-based treatments [3]. In the ABC
superfamily, P-gp plays a key role in mediating the highest resistance to bulky anticancer
agents [4]. It’s a well-characterized transportor which is widely overexpressed in both solid
tumors and haematological malignancies with a broad spectrum of substrate specificity [5].
Functioning as a drug efflux pump, P-gp prevents cytotoxic agents from reaching effective
concentrations within cells. PTX has been shown to be a high affinity substrate a P-
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glycoprotein encoded by the multidrug resistance 1 (MDR1) gene, which hinders its
successful therapy in cancers. To address this problem, P-gp inhibitors such as verapamil,
quinine and cyclosporin A have been introduced to reverse MDR since the early 1980s [6].
However, clinical trials failed to show significant benefit. The efficacy of these inhibitors
was largely compromised by pharmacokinetics interactions and increased side effects [7–8].
Another limitation of the clinical application of PTX is its low solubility in water (<1 μg/
ml). Currently, two commercially available formulations of PTX are Taxol and Abraxane.
Taxol is based on a 1:1 (v/v) mixture of polyoxyethylated castor oil (Cremophor EL or
simply Cremophor) and dehydrated ethanol. Notably, Cremophor is responsible for some
severe side effects such as hypersensitivity reaction and peripheral neurotoxicity [9]. To
address these issues, Abraxane was approved by US FDA in 2005. This Cremophor-free
formulation delivers PTX as a suspension of albumin particles in saline, which eliminates
the solvent-related toxicities [10]. However, the preparation of Abraxane requires high-
pressure homogenization of PTX in the presence of human serum albumin, resulting in the
high cost of the dosage form [11]. Most importantly, there is no evidence that Abraxane has
activities against MDR tumors. Thus, novel Cremophor-free formulations of PTX for
overcoming MDR are still highly desirable.
Nanotechnology offers an unprecedented opportunity in drug delivery to tumors. These
nano-based delivery systems provide many promising features for overcoming MDR:
enhanced delivery to tumor tissues, optimized pharmacokinetics and delivery of multiple
therapeutic agents in a single formulation.[12]. In this study Paclitaxel (PTX) nanocrystals
were prepared using D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) as the sole
excipient. TPGS was selected for this study for several reasons. First, it has been recognized
as one of the most potent P-gp inhibitors among many different surfactants, which can
function at a concentration well below critical micelle concentration (CMC) [13–14].
Second, it has long-standing safety record in biomedical applications as a water-soluble
derivative of natural vitamin E. In addition, TPGS lacks unrelated pharmacological effects
and shows no pharmacokinetic interactions with other drugs.
Experimental Section
Material and experimental animals
Paclitaxel (PTX) was bought from Lc Laboratories (Woburn, MA). TPGS was bought from
Eastman (Anglesey, UK). Pluronic F-127 (F127), Cremophor-EL were purchased from
Sigma-Aldrich (St. Louis, MO).
Female BALB/c nude mice (5 weeks old) were purchased from National Cancer Institute
U.S. National Institute of Health (NCI, Frederick, MD). All work performed on animals was
in accordance with and permitted by the University of North Carolina Institutional Animal
Care and Use committee.
Resistant human ovarian cancer cell line, NCI/ADR-RES, was a kind gift from Dr. Russell
Mumper (UNC-Chapel Hill, Chapel Hill, NC). Cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) GlutaMAX™ medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA). Human lung cancer cell
line, NCI-H460, and human nasopharynx carcinoma cell line, KB cells were obtained from
American Type Culture Collection. Cells were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA).
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The nanocrystals were prepared by the method of the stabilization of nanocrystal (SNC)
[15]. Briefly, PTX and TPGS were first dissolved in chloroform (in a glass tube) with
different ratios (1:1~1:5, w/w) and co-precipitated by evaporating the chloroform with a
steady flow of nitrogen gas. Trace amount of chloroform was removed by keeping the
precipitates under a vacuum in a desiccator for 2 to 4 h. Following 20 min hydration in
water and vortex, suspensions were sonicated for 10 to 15 min in a bath-type sonicator
(output 80 kc, 80 Watts) to form nanocrystals.
Characterization of nanocrystals
Particle size and morphology were determined by transmission electron microscope (TEM)
with an acceleration voltage of 100 kV. To prepare the samples, PTX/TPGS nanoparticle
nanocrystals (5μL) was deposited onto a 200 mesh copper grid coated with carbon (Ted
Pella, Inc., Redding, CA), allowed to stand for 5 min, and excess liquid was wicked off.
Samples were stained with 1% uranyl acetate (5μL), followed by overnight air drying at
room temperature. Images were acquired using a JEOL 100CX II TEM.
The structure of PTX/TPGS nanocrystals was studied by powder X-ray diffraction(XRD).
PTX/TPGS nanocrystals suspension was lyophilized to obtain powders. Pure PTX crystals
were prepared using the same method. Then the XRD diagrams were collected in a Rigaku
Multiflex powder diffractometer.
To assess the release kinetics, dialysis cassettes (molecular weight cut-off 10,000 dalton)
were filled with 1ml of different PTX formulations and immersed in 400 ml dialysis buffer
(PBS (pH 7.4) containing 0.05% Tween 80). Taxol which is the clinical paclitaxel
formulation in Cremophor EL and dehydrated USP-grade ethanol (1:1, v/v) was used as a
control. At designated time points, aliquots of 2ml buffer were sampled and replaced with
the same volume of fresh dialysis buffer. The whole volume of dialysis buffer was replaced
at selected time intervals to maintain a sink condition. One μg (10 μl) of n-butyl p-hydroxy-
benzoate was added to the aliquots as an internal standard (STD). PTX and STD were
extracted by a liquid-liquid extraction with methyl tert-butyl ether. After the evaporation of
methyl tert-butyl ether by nitrogen stream, the residue was dissolved with the mobile phase
(methanol: water=80:20) and quantified by HPLC. The HPLC system was performed at a
flow rate of 1.0 ml/min at 228 nm with a UV detector, using a 25mm×4.6mm reverse phase
C18 column.
The stability of PTX/TPGS nanocrystals was investigated at room temperature and 37°C.
PTX/F127 nanocrystals which were developed in our lab previously served as a control. At
intervals of specified time, the particle size and distribution of nanocrystals were measured
using a submicron particle sizer (NICOMP particle sizing systems, AutodilutePAT Model
370, Santa Barbra, CA) in the NICOMP mode.
Cytotoxicity on sensitive and resistant cancer cells
To evaluate cytotoxicity of PTX/TPGS nanocrystals, MTT (3-[4,5-dimethylthiazole-2-
yl]-2,5-diphenyl-tetrazolium bromide) assay was performed on NCI/ADR-RES, KB and
H460 cells. Briefly, cells were seeded into 96-well plates at a concentration of 1×104 cells/
well in a volume of 200μl/well. After 24h, the medium was removed and 200 μl fresh
medium containing 5μM of PTX in various formulations were added, including PTX/TPGS
nanocrystals, PTX/F127 nanocrystals, Taxol and free PTX. Free PTX was prepared by
dissolving PTX in chloroform and processing by the method of SNC as described above
except without TPGS. To study the influence of the amount of surfactant on cytotoxicity,
fresh medium containing PTX/TPGS nanocrystals and PTX/TPGS mixture with different
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drug/surfactant ratios were added, where PTX concentration was kept at 10 μM. Dose
dependent cytotoxicity of various PTX formulations was also evaluated, including PTX/
TPGS nanocrystals, PTX/F127 nanocrystals, Taxol and free PTX. Following a 43 h period
of incubation, 5μl MTT (5mg/ml) was added to each well. The plates were incubated for an
additional 5 h. Then the supernatants were carefully aspirated, 200μl dimethyl sulfoxide was
added to each well to dissolve the crystal product. The absorbance values were read on a
microplate reader using a Bio-Rad Microplate Imaging System (Hercules, CA) at the
wavelength of 570 nm. Cell viability was calculated using the following formula: viability%
= (A570nm for the treated cells/A570nm for the control cells)×100, where A570nm is the
absorbance.
Assessment of apoptosis by Annexin-V/PI staining
Cellular apoptosis was assessed using flow cytometry. In brief, NCI/ADR-RES cells were
seeded in a 6-well plate at a concentration of 2×105 cells/well. 24h later, PTX/TPGS
nanocrystals, Taxol, TPGS and PBS were added. PTX concentration was 5μM in both PTX/
TPGS nanocrystals and Taxol. In surfactant alone group, TPGS concentration was the same
as that in PTX/TPGS nanocrystals group. After 48h treatment, the cells were harvested,
washed and stained with annexin-V/propidium iodide (PI) according to the manufacturer’s
instruction. Apoptotic cells were measured by BD FACS Canto™ flow cytometer (BD
Biosciences, San Jose, CA).
in vivo anticancer effects
5 ×106 NCI/ADR-RES cells were injected subcutaneously into the right flanks of nude mice
for inoculation. Once the tumor mass in the xenograft was established, mice were randomly
assigned to treatment groups (5 mice per group) and intravenously injected with different
formulations of PTX at the dose of 10mg/kg each single dose or TPGS alone at the dose of
50mg/kg each single dose. 50mg/kg of TPGS was given in order to keep consistent with the
drug/surfactant ratio used in in vitro studies. Treatments were conducted on day 0, 3, 6, 9,
12. Tumor volume were measured every other day, which were calculated as (length ×
width2)/2. Mice were sacrificed when the long dimension of the tumor reached 2 cm.
Statistics
Data are presented as the mean ± standard deviation. One-way analysis of variance
(ANOVA) was used to determine significance among groups in animal studies. For stability
and cytotoxicity studies, statistical analyses were performed by a two-tailed student t-test. A
value of p < 0.05 was considered to be significant.
Results
Characterization of PTX/TPGS nanocrystals
PTX/TPGS nanocrystals were prepared using TPGS as the single excipient. Different drug/
surfactant ratios were investigated (1:1~1:5, w/w). The results showed that the ratio didn’t
affect the size and morphology of the nanocrystals. Fig. 2A and 2B show PTX/TPGS
nanocrystals with boundary drug/surfactant ratios (1:1 and 1:5, w/w). They all exhibited rod
shape with moderate uniform particle size. The average width is about 40nm and the length
is around 150nm. When the ratio was lower than 1/1 (further decrease of the amount of
TPGS), the nanocrystals could not be formed. Thus, the maximum drug loading ratio of the
TPGS nanocrystals was found to be as high as 50%. TPGS can also form nanoparticles with
other hydrophobic drugs such as Itraconazole, as shown in Fig 2C, indicating a broader
application.
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XRD was performed to study the structure of the rod-shaped particles. As shown in Fig. 3,
the presence of a large number of Bragg peaks in the diffraction patterns is indicative of a
crystalline structure. Although pure PTX has a fairly flat background and sharper peaks than
PTX/TPGS nanocrystals, the two diagrams are very similar and almost superimposable.
The in vitro drug release profile PTX/TPGS nanocrystals was assessed in an effort to
determine whether PTX would be released from nanocrystals prior to cellular uptake. As
depicted in Fig. 4, PTX/TPGS nanocrystals have a substantially sustained release profile
compared with Taxol. The cumulative release of PTX after 72 h was about 50% from PTX/
TPGS nanocrystals. While in Taxol, PTX was encapsulated in micelles of Cremophor,
resulting in a rapid release (100% within 22 h). No initial burst release of PTX was observed
for nanocrystals, which indicated that PTX was not likely to present at or near the surface of
the nanocrystals. Instead PTX was shelled by the nonionic surfactants coated on the surface
of the nanocrystals. This assumption was supported by X-ray photospectrometer (XPS). To
prove the successful surface coating of TPGS on PTX, the nitrogen atom which only exists
in PTX molecules was specifically scanned and the absence of nitrogen signal verified the
coating. Pure PTX crystals exhibited a relatively rapid release, which is understandable,
because there isn’t any surfactant coated on the surface.
Particle size of nanocrystals was measured to evaluate the stability. As shown in Fig. 5, the
size of PTX/TPGS nanocrystals remained stable at room temperature for more than two
weeks, while the size of PTX/F127 nanocrystals dramatically increased. Moreover, PTX/
TPGS nanocrystals are stable at 37°C for 5 days while PTX/F127 nanocrystals aggregated
within hours. The drug/surfactant ratio didn’t affect the thermostability since 1:1 and 1:5 (w/
w) PTX/TPGS nanocrystals exhibited comparable stability, as shown in Fig. 4B.
Effect on sensitive and resistant cancer cells IN VITRO
Fig. 6 summarized the anti-proliferation effect of various formulations of PTX on a panel of
human cancer cells. In KB and H460 cells, PTX/TPGS nanocrystals, PTX/F127
nanocrystals, Taxol and free PTX all greatly inhibited cell proliferation. There was not any
significantly difference among the four treatments. However, in NCI/ADR-RES cells, which
overexpress P-gp and are resistance to PTX, PTX/F127 nanocrystals, and free PTX become
almost ineffective. Taxol had a moderate inhibition of cell growth in resistant cells. PTX/
TPGS nanocrystals exhibited significantly enhanced anti-proliferation effect in NCI/ADR-
RES cells over other formulations, which inhibited cell growth by 40%, as shown in Fig.
6A. The amount of surfactant affected cytotoxicity of PTX/TPGS nanocrystals in NCI/
ADR-RES cells. As shown in Fig. 6B, as the amount of surfactant increased, the anti-
proliferation effect of PTX/TPGS nanocrystals increased, either in PTX/TPGS nanocrystals
or mixture, indicating that TPGS is modulating drug resistance transporters. However, at
low surfactant concentration, PTX/TPGS nanocrystals are more cytotoxic than PTX/TPGS
mixture, whereas at high surfactant concentration they are comparable. In the dose
dependent assay shown in Fig. 6C, PTX/F127 nanocrystals or free PTX alone didn’t show
significant inhibition in NCI/ADR-RES cells even at the concentration of 30μM. However,
PTX/TPGS nanocrystals could effectively reverse the resistance and inhibited cell growth
with an IC50 around 5μM. Taxol can also overcome the resistance but is less effective than
PTX/TPGS nanocrystals.
Apoptosis assay in resistance cancer cells
Since apoptosis is the predominant mechanism of cell death in response to taxane
chemotherapy [16], apoptosis-inducing effect of nanocrystals was assessed using Annexin-
V/PI staining. Apoptotic percentages were calculated based on the cells stained with
annexin-V (FITC) alone (early apoptosis) and doubly stained with both annexin V and PI
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(late apoptosis). It was shown that all the treatment could induce certain amounts of
apoptosis in NCI/ADR-RES cells (Fig. SI1). For example, the early and late apoptosis
percentages for Taxol were 19.4% and 7.1%, respectively. TPGS alone can also induce
11.4% of early apoptosis and 18.6% of late apoptosis. However, PTX/TPGS nanocrystals
showed the most significant apoptosis-inducing effect. After applying PTX/TPGS
nanocrystals, the apoptotic percentage dramatically increased to more than 95%. This result
was consistent with the cytotoxicity results above.
Antitumor efficacy in tumor xenografts models
Fig. 7 describes the therapeutic efficacy following applying various formulations to the NCI/
ADR-RES xenografts in nude mice. TPGS alone did not show any significant antitumor
efficacy in vivo. Even Taxol given at a dose of 10 mg/kg was generally ineffective in
inhibiting tumor growth, indicating that NCI/ADR-RES xenografts are truly resistant.
However, an obvious tumor regression was observed in animals treated with10 mg/kg of
PTX/TPGS nanocrystals, indicating a significantly enhanced tumor inhibition effect over
Taxol (p <0.01), as shown in Fig. 7.
Body weight of mice was also measured throughout the study. No weight loss occurred in
the mice treated with PTX/TPGS nanocrystals (data not shown), indicating that this
formulation of PTX was well tolerated.
Discussion
As shown in the results, the TPGS based PTX nanocrystals reported here have several
unique features. First, the stable PTX nanocrystals were formulated with a P-gp inhibitor
(i.e. TPGS) as a sole excipient. The ability of overcoming MDR phenotype both in vitro and
in vivo makes this formulation more significant. Second, TPGS served dual functions in this
formulation: stabilizing the nanocrystals and inhibiting P-gp activity. Third, the nanocrystals
exhibited a high capacity of drug-loading compared to Taxol and Abraxane, which may lead
to decreased infusion time or change of administration routine. Another advantage of
nanoparticles which exhibit a high ratio of drug to excipitent is upon entering the target
cells, the nanoparticles will unload an increased amount of the drug to the cells and therefore
maximize therapeutic efficacy. Moreover, since the preparation is easy to scale up and the
excipient is readily available, the formulation is cost-effective and has a potential for
development. TPGS stabilized and solubilized PTX nanocrystals by coating the outside,
which was confirmed by XPS (data not shown). This stabilized crystalline structure prevents
the nanocrystals from aggregation through storage and gives slow release kinetics.
In cytotoxicity study, it is not surprising to find that Taxol had some activity against
resistant cells, although it was not as effective as PTX/TPGS nanocrystals, because
Cremophor can modulate MDR by inhibition of the efflux pumps [17]. However, it is worth
noticing that the concentration of Cremophor in Taxol was 16 fold higher than the
concentration of TPGS in nanocrystals. It is not feasible to achieve such a high
concentration in vivo to bring any clinical benefit since Cremophor is well known for its
toxicity. Apoptosis assay was also conducted, showing that PTX/TPGS nanocrystals were
more potent than Taxol in killing tumor cells through the apoptosis-inducing mechanism,
which is accepted as the predominant mechanism of cell death in response to taxane
chemotherapy [16]. It appeared that TPGS alone could be slightly cytotoxic for in vitro
study while in vivo results demonstrate that TPGS has no antitumor effect. This could be
understood since surfactants at a relatively high concentration in in vitro study resulted in
lysis of cells. Slow release rate of PTX from PTX/TPGS nanocrystals dose not contradict its
enhanced cytotoxicity since TPGS inhibits drug resistance transporters in a dose- dependent
manner. Besides, nanocrystals can be internalized by cells via endocytosis, resulting in a
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higher intracellular concentration of PTX. The clear mechanism need to be further
elucidated by cellular uptake study. It was shown that at high surfactant concentration PTX/
TPGS mixtures showed comparable cytotoxicity as PTX/TPGS nanocrystals. One possible
explanation is that at high concentration above critical micelle concentration of TPGS, extra
TPGS starts to coat PTX and form micro- or nanocrystals during sonication. Therefore, the
resulted formulation behaves more like nanocrystals rather than simple mixture.
PTX/TPGS nanocrystals exhibited significant improved antitumor effect compared to Taxol
in the Taxol-resistant NCI/ADR-RES cells especially in vivo. It could be attributed the
inhibition of P-gp function by TPGS, as we hypothesized in formulation design. Meanwhile,
the slow release of PTX from the stabilized nanocrystals may lead to a longer half life of
PTX, resulting in enhanced efficacy. The nano size of the particles may also contribute to
the antitumor effect, since it has long been established that small size particles intend to
penetrate into interstitium of tumor through leaky vasculature [18]. As PTX and TPGS were
co-delivered in the same carrier simultaneously, they are more like to have synergism in
antitumor effects. Pharmacokinetics and biodistribution studies are needed to further
elucidate the mechanism.
Generally speaking, when tumors develop resistance to a certain drug (about 50% of total
cancer cases) [19], physicians have to switch to another chemotherapeutic agent or radiation
to circumvent this resistance. To make things worse, cancer cells often develop resistance to
different drugs, which was described above as MDR. PTX/TPGS nanocrystals overcome
MDR elicited by PTX alone, providing an alternative for the treatment of MDR. A similar
strategy to overcome MDR has been reported recently by Dong et al. using paclitaxel-loaded
lipid-based nanoparticles which also include TPGS as one of the excipients [20]. A lot of
cancer drugs, such as etoposide and camptothecin, are substrates of P-gp due to their
hydrophobicity. Therefore, this approach could potentially extend to this type of drugs,
where the issue of solubility and MDR could be addressed at the same time.
In conclusion, we have demonstrated that PTX/TPGS nanocrystals can provide a variety of
benefits including high drug loading capacity, high stability, sustained release, and most
importantly, the ability to overcome MDR both in vitro and in vivo. This nano-scaled
formulation may provide a novel strategy for overcoming multidrug resistance in cancer
therapy.
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Structure of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS).
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Transmission electron microscope images of PTX formulations. A: PTX/TPGS nanocrystals
with the ratio of 1:1 (w/w); B: PTX/TPGS nanocrystals with the ratio of 1:5 (w/w); C:
Itraconazole/TPGS particles with the ratio of 1:5 (w/w). Scale bars represent 200 nm.
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Powder XRD patterns of pure PTX crystals and PTX/TPGS nanocrystals.
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In vitro release profiles of PTX from Taxol and PTX/TPGS nanocrystals.
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Stability of PTX/TPGS nanocrystals. (A) PTX/F127 nanocrystals size increased upon
storage at room temperature while PTX/TPGS nanocrystals size remained the same; (B)
PTX/F127 nanocrystals size increased at 37°C while PTX/TPGS nanocrystals size remained
the same. (PTX=586 μM)
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Cell viability after being treated with different formulations for 48 h. A: Effects of PTX/
TPGS nanocrystals, PTX/F127 nanocrystals, Taxoland PTX at the same 5 μM PTX
concentration on NCI/ADR-RES, KB and H460 cells; B: Effects of PTX/TPGS nanocrystals
(10 μM) with different amount of TPGS and PTX/TPGS mixture (10 μM) with different
amount of TPGS; C: Dose-dependent response of PTX/TPGS nanocrystals, PTX/F127
nanocrystals, Taxol and PTX on NCI/ADR-RES cells.
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Tumor growth inhibition effect of PTX/TPGS nanocrystals, Taxol and TPGS alone in the
NCI/ADR-RES xenograft model. Solid arrows indicate the days of intravenous
administration.
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